Validation study of the modified injection technique for internal mammary sentinel lymph node biopsy in breast cancer

This article was published in the following Dove Press journal:
OncoTargets and Therapy
24 September 2015
Number of times this article has been viewed

Abstract: According to the hypothesis of internal mammary sentinel lymph node (IM-SLN) lymphatic drainage pattern, a modified radiotracer injection technique (periareolar intraparenchyma, high volume, and ultrasonographic guidance) was established. To verify the accuracy of the hypothesis and validate the modified radiotracer injection technique and to observe whether the lymphatic drainage of the whole breast parenchyma could reach to the same IM-SLN, different tracers were injected into different locations of the breast. The validation study results showed that the correlation and the agreement of the radiotracer and the fluorescence tracer are significant (case-base, $r_s=0.808$, $P<0.001$; Kappa =0.79, $P<0.001$). It proved that the lymphatic drainage from different location of the breast (the primary tumor, the subareolar plexus) reached the same IM-SLNs and the hypothesis of IM-SLN lymphatic drainage pattern (ie, IM-SLN receives lymphatic drainage from not only the primary tumor area, but also the entire breast parenchyma). In other words, it validated the accuracy of our modified radiotracer injection technique.

Keywords: breast cancer, internal mammary, sentinel lymph node biopsy, visualization rate

Introduction
Cao et al have emphasized the importance of internal mammary sentinel lymph node biopsy (IM-SLNB) and have described a modified radiotracer injection technique that could significantly improve the visualization rate of the internal mammary sentinel lymph node (IM-SLN). Even though the TNM staging of the sixth American Joint Committee on Cancer incorporated the concept of IM-SLNB, IM-SLNB is not routinely performed and remains a subject of discussion. One reason is the low visualization rate of IM-SLN with the traditional radiotracer injection technique (range from 0% to 37%, mean 13%). The other reason is previous IM-SLNB clinical trials failed to evaluate the status of internal mammary lymph node (IMLN) in patients who were really in need (only in patients with clinically negative axillary lymph node [ALN]), because IMLN metastases were mostly found concomitantly with ALN metastases.

Modified radiotracer injection technique
Current evidence has proved that the axillary sentinel lymph node (ASLN) receives the lymphatic drainage from not only the primary tumor area but also the entire breast organ. Tanis et al described that the breast parenchyma has extensive lymphatic network and has rich anastomoses with the superficial cutaneous lymph plexus of the developing skin. It is considered that radiotracer, wherever injected, could flow to the same ASLN.
Based on the earlier concept of ASLN, we hypothesized that the IM-SLN received lymphatic drainage from not only the primary tumor area but also the entire breast parenchyma (in other words, the radiotracer could flow to the same IM-SLN wherever injected). According to the hypothesis of IM-SLN lymphatic drainage pattern, a modified radiotracer injection technique (periareolar intraparenchymal, high volume, and ultrasonographic guidance) was established. In comparison with the traditional radiotracer injection technique, the modified radiotracer injection technique significantly enhanced the visualization rate of IM-SLN without lowering the ASLN visualization rate (99.4%, 155/156 in the validation study), thus providing the technical feasibility for IM-SLNB and improving the pathological stage.

Validation procedure

The accuracy of axillary sentinel lymph node biopsy (SLNB) has been proved by subsequent axillary lymph node dissection. However, the accuracy of IM-SLN has not been confirmed. As the extended radical mastectomy has been abandoned since 1960s, we cannot validate the accuracy of IM-SLN and the modified technology by this way. Recently, a validation study about the accuracy of the modified technique was designed and performed by our team in our breast cancer center. The study was approved by the Shandong Cancer Hospital and Institute Ethics Committee (No SDTHEC20130324). Written, informed consent was obtained from all patients. In the validation study, the indocyanine green (ICG) fluorescence tracer, which is a safe and effective method for SLNB in breast cancer with acceptable sensitivity and specificity comparable to conventional methods (blue dye and radiotracer), and the radiotracer were injected into different locations of the breast to observe whether the lymphatic drainage of the whole breast parenchyma could reach the same IM-SLN.

A total of 156 patients with breast cancer were enrolled in this study from September 2013 to December 2014. The radiotracer (99mTc-labeled sulfur colloid, 1.0–1.2 mL, 9.25–18.5 MBq) was injected with our modified radiotracer injection technique, and the injection sites were chosen at the 6 and 12 o’clock positions, 0.5–1.0 cm from the areola, under ultrasonographic guidance 3–18 hours before surgery. All patients underwent a preoperative lymphoscintigraphy (Toshiba GCA 901AHG; Toshiba, Tokyo, Japan) 30 minutes before surgery and a gamma probe (Neoprobe, Neo2000 gamma detection system; Johnson & Johnson New Brunswick, NJ, USA) detection 10 minutes before surgery. Radioactive IM-SLNs was defined as IM-SLNs visualized on preoperative lymphoscintigraphy (Figure 1) and detected by gamma probe. Patients with radioactive IM-SLNs were injected with ICG 5 minutes before surgery. A total of 2 mL 0.5% ICG was intraparenchymally injected under the ultrasonographic guidance at the peritumoral near the subareolar region to differentiate it from the radiotracer. IM-SLNB was performed for patients with the radioactive IM-SLNs. The fluorescent signal of IM-SLN was identified by the fluorescence imaging system (Mingde, MD fluorescence imaging system, Langfang, People’s Republic of China; Figure 2). The flowchart of the validation study is shown in Figure 3.

In this study, IM-SLNs were visualized on preoperative lymphoscintigraphy and detected by gamma probe in 112 cases, and the IM-SLN visualization rate was 71.8% (112/156). A total of 110 of them successfully underwent IM-SLNB, so the success rate of IM-SLNB was 98.2% (110/112). There were 94 patients with the IM-SLN verified both radioactive and fluorescence tracer positive, and 16 patients with the IM-SLN only verified radiotracer positive. The other 44 cases found no IM-SLN with either radioactive or fluorescence tracer positive. The results showed that the correlation and the agreement of the radiotracer and the fluorescence tracer are significant (case-base, $r = 0.808, P < 0.001$; Kappa = 0.79, $P < 0.001$). The median number of IM-SLNs was 2 (total 198, range: 1–4 nodes). The IM-SLNs were located in the first (6.0%, 12/198), second (46.5%, 92/198), third (39.9%, 79/198) and forth (7.6%, 14/198) intercostal spaces (Figure 2).
Figure 2. Intraoperatively IM-SLN via intercostal space. Note: The fluorescence imaging system (A) showed an IM-SLN fluorescence tracer positive in the fourth intercostal space (arrow) in patient after mastectomy (B). Abbreviations: IM-SLN, internal mammary sentinel lymph node; IM-SLN, internal mammary sentinel lymph node biopsy.

Conclusion
The results of our validation study showed that the lymphatic drainage from different locations of the breast (the primary tumor, the subareolar plexus) reached to the same IM-SLNs. On the one hand, it is proved that the nodes that are detected by IM-SLNBI could drain not only the regional of the primary tumor but also the entire mammary glands. On the other hand, it is proved that the IM-SLN that was removed by IM-SLNBI should be the “true” sentinel nodes. In conclusion, our study provided a factual basis to clarify the concept of IM-SLN and validated the accuracy of IM-SLNBI and our modified radiotracer injection technique.

15/198 (64.7%, 11/17) intercostal space, all positive IM-SLNs were in the second (64.7%, 11/17) and third (35.3%, 6/17) intercostal space. The involvement rate of IM-SLN was 6.8% (5/73) in patients with clinically negative ALN and 21.6% (8/37) in patients with clinically positive ALN. These results were in accordance with past studies of extended radical mastectomy. It can indirectly reflect the accuracy of our results. In six patients, the nodal pathological staging altered from pN\textsubscript{2a} to pN\textsubscript{3b}, causing a stage migration from IIIA to IIIC. Moreover, in five patients, the nodal pathological status changed from pN\textsubscript{0} to pN\textsubscript{1b}, resulting in the change of stage from IIA to IIB.

Figure 3. Flowchart of the validation study. Abbreviations: ICG, indocyanine green; IM-SLNBI, internal mammary sentinel lymph node biopsy.
Disclosure
The authors report no conflicts of interest in this work.

References